Wird geladen...
Are We Ready to Use ESR1 Mutations in Clinical Practice?
The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers....
Gespeichert in:
| Veröffentlicht in: | Breast Care (Basel) |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
S. Karger GmbH
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5704725/ https://ncbi.nlm.nih.gov/pubmed/29234250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481428 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|